Patent: 9,931,399
✉ Email this page to a colleague
Summary for Patent: 9,931,399
| Title: | Adjuvanted formulations of booster vaccines |
| Abstract: | The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response. |
| Inventor(s): | Barbara Baudner, Derek O'Hagan, Manmohan Singh, Simone BUFALI |
| Assignee: | GlaxoSmithKline Biologicals SA |
| Application Number: | US15/163,592 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,931,399
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | BOOSTRIX | tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed | Injection | 125106 | May 3, 2005 | 9,931,399 | 2036-05-24 |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | 25-Sep-15 | 9,931,399 | 2036-05-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,931,399
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013132041 | ⤷ Start Trial |
| United States of America | 9375471 | ⤷ Start Trial |
| United States of America | 2018177871 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
